|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2003-3-14
|
|
pubmed:abstractText |
The combination of radiation, fluorouracil, and oxaliplatin in locally advanced rectal cancer has been shown to be feasible in a phase I trial. The purpose of this phase II trial was to assess tolerance and efficacy of this regimen in a preoperative setting.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1119-24
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:12637479-Adenocarcinoma,
pubmed-meshheading:12637479-Adult,
pubmed-meshheading:12637479-Aged,
pubmed-meshheading:12637479-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12637479-Chemotherapy, Adjuvant,
pubmed-meshheading:12637479-Drug Administration Schedule,
pubmed-meshheading:12637479-Female,
pubmed-meshheading:12637479-Fluorouracil,
pubmed-meshheading:12637479-Humans,
pubmed-meshheading:12637479-Leucovorin,
pubmed-meshheading:12637479-Male,
pubmed-meshheading:12637479-Middle Aged,
pubmed-meshheading:12637479-Neoadjuvant Therapy,
pubmed-meshheading:12637479-Organoplatinum Compounds,
pubmed-meshheading:12637479-Radiotherapy, Adjuvant,
pubmed-meshheading:12637479-Radiotherapy Dosage,
pubmed-meshheading:12637479-Rectal Neoplasms,
pubmed-meshheading:12637479-Treatment Outcome
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial.
|
|
pubmed:affiliation |
Department of Radiation Oncology, Lyon Sud Pierre Bénite, France. jean-pierre.gerard@cal.nice.fnclcc.fr
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
